IMscin001 第二部分:一项随机III期、开放标签、多中心研究,比较阿替利珠单抗皮下与静脉给药在既往治疗过的局部晚期或转移性非小细胞肺癌中的药代动力学、疗效、免疫原性和安全性,并与其他已批准适应症的药代动力学比较
IMscin001第二部分是一项随机III期开放标签多中心非劣效研究,比较阿替利珠单抗皮下(1875 mg,n=247)与静脉(1200 mg,n=124)每3周给药在局部晚期/转移性非小细胞肺癌患者中的药代动力学。研究达到两个共同主要终点:第1周期谷浓度和模型预测AUC0-21d的非劣效性;疗效、安全性和免疫原性两组相似,皮下给药药代动力学与其他已批准静脉适应症一致。
要点
- 皮下阿替利珠单抗第1周期谷浓度非劣效于静脉给药,几何均值比1.05(90%CI 0.88-1.24)。
- 皮下与静脉给药的疗效、安全性和免疫原性相似,未发现新的安全性问题。
- 皮下阿替利珠单抗的药代动力学与其他已批准静脉适应症一致。
核心结论
- 与静脉给药相比,阿替利珠单抗皮下给药在第1周期显示非劣效的药物暴露。
- 两组疗效、安全性和免疫原性相似,且与阿替利珠单抗静脉给药的已知特征一致。
- 皮下与静脉给药后相似的药物暴露和临床结局支持皮下阿替利珠单抗作为静脉给药的替代选择。
研究设计与样本
- IMscin001第二部分(NCT03735121)是一项随机III期、开放标签、多中心、非劣效研究。
- 符合条件的局部晚期/转移性非小细胞肺癌患者按2:1随机接受阿替利珠单抗皮下1875 mg(n=247)或静脉1200 mg(n=124),每3周给药。
主要发现
- 第1周期观察谷浓度:皮下组89 μg/ml(变异系数43%)vs 静脉组85 μg/ml(变异系数33%),几何均值比1.05(90%CI 0.88-1.24)。
- 第1周期模型预测AUC0-21d:皮下组2907 μg·d/ml(变异系数32%)vs 静脉组3328 μg·d/ml(变异系数20%),几何均值比0.87(90%CI 0.83-0.92)。
- 无进展生存期风险比1.08(95%CI 0.82-1.41),客观缓解率皮下组12% vs 静脉组10%,抗阿替利珠单抗抗体发生率皮下组19.5% vs 静脉组13.9%,两组相似。
- 未发现新的安全性问题。
- 皮下阿替利珠单抗的谷浓度和AUC0-21d与其他已批准的阿替利珠单抗静脉适应症一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atezolizumab intravenous (IV) is approved for the treatment of various solid tumours. To improve treatment convenience and health care efficiencies, a coformulation of atezolizumab and recombinant human hyaluronidase PH20 was developed for subcutaneous (SC) use. Part 2 of IMscin001 (NCT03735121) was a randomised phase III, open-label, multicentre, noninferiority study comparing the drug exposure of atezolizumab SC with atezolizumab IV. PATIENTS AND METHODS: Eligible patients with locally advanced/metastatic non-small-cell lung cancer were randomised 2 : 1 to receive atezolizumab SC (1875 mg; n = 247) or IV (1200 mg; n = 124) every 3 weeks. The co-primary endpoints were cycle 1 observed trough serum concentration (Ctrough) and model-predicted area under the curve from days 0 to 21 (AUC0-21 d). The secondary endpoints were steady-state exposure, efficacy, safety, and immunogenicity. Exposure following atezolizumab SC was then compared with historical atezolizumab IV values across approved indications. RESULTS: The study met both of its co-primary endpoints: cycle 1 observed Ctrough {SC: 89 μg/ml [coefficient of variation (CV): 43%] versus IV: 85 μg/ml (CV: 33%); geometric mean ratio (GMR), 1.05 [90% confidence interval (CI) 0.88-1.24]} and model-predicted AUC0-21 d [SC: 2907 μg d/ml (CV: 32%) versus IV: 3328 μg d/ml (CV: 20%); GMR, 0.87 (90% CI 0.83-0.92)]. Progression-free survival [hazard ratio 1.08 (95% CI 0.82-1.41)], objective response rate (SC: 12% versus IV: 10%), and incidence of anti-atezolizumab antibodies (SC: 19.5% versus IV: 13.9%) were similar between arms. No new safety concerns were identified. Ctrough and AUC0-21 d for atezolizumab SC were consistent with the other approved atezolizumab IV indications. CONCLUSIONS: Compared with IV, atezolizumab SC demonstrated noninferior drug exposure at cycle 1. Efficacy, safety, and immunogenicity were similar between arms and consistent with the known profile for atezolizumab IV. Similar drug exposure and clinical outcomes following SC and IV administration support the use of atezolizumab SC as an alternative to atezolizumab IV.
引用
- Burotto M, Zvirbule Z, Mochalova A, et al. IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications. Ann Oncol. 2023. PMID: 37268157. doi:10.1016/j.annonc.2023.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。